EZH2 and breast carcinoma: In a recent in vitro breast cancer study of miR-600, a low expression of miR-600, the inhibition of its downstream target enhancer of zeste homolog 2 (EZH2), an oncogenic histone methyltransferase, and EZH2’s inhibition of tumor suppressor gene runt-related transcription factor 3 (RUNX3), have been shown to cause sorafenib resistance [33].